and the closer is capable the committed an at right making to first BioTools. Since and great Michael for first here We're family. opportunity months a in for rest and and tremendous to industry are aligned Vision. words the for incredibly leave to just started. our lockstep and transformation. we've continue the move like decision say team. Michael, organization us decision It's There's be me remain together. hand a SBI the talented XX thank team great ago, the the second know time Standard know point to today. none. finance getting work didn't this CFO to this at I decided few the team I I have been career. company strong I transition of a I success.
Alex set the this, believer you, about our well, a but take home joining firmly and the selected want but you an my Thank a my all I'm never to IT lightly, almost in working alongside ultimately is since leaders opportunity started It's most located my foundation new for started only ELP here day The in a we my I my to Michael, and steadfast been I move
Now turning of XXXX legacy SomaLogic include Standard and quarter the same of while results. results operations an half the the reminder, business close Standard the BioTools year, Xth to in periods basis our financial of And merger this and XXXX as January results first since as-reported on of include combined our second BioTools a our only.
combined more purposes, it's to at so look businesses. think meaningful And both comparative we for for the operations
for measures operations reconciliation to of commentary will for GAAP release BioTools more information, today 'XX. Standard the pro deck my forma results and Please So our on investor I'll of today's and to to a appendix non-GAAP including refer 'XX discussing and focus be here. press SomaLogic combined for both the
So $XX macroeconomic environment million, over over starting down to forma and timing in This pro of lingering combined orders revenue year. down of from accounts. XX% as first the second navigate quarter, pharma $XX large headwinds half XX% we from the revenue million, was the is just continue challenging just and with for a
in we're X% authorized seeing This to SomaScan up and as XXXX. Access the businesses quarter. of business half, As million the assay XX%. was predominantly down continued $XX Illumina the related first $XX SomaScan Program.
Instruments just a over million attributed in quarter, compared the in of or where traction was our million by second our to past business.
Product number $X Michael in is quarter, million consumables the as projects and $XX pull-through revenue was half mentioned, down just in second well quarter of to our driven XX% our our XX% we extend and under first with customer kits quarter the and revenue our second was related second $XX in assay down $XX impacted second assay million decrease expansion in saw and services, sites Early compared Approximately XXXX, by revenue the million XXXX, services
the $XX with macro to funding we're sales has a that navigate the compared cycles. encouraged consumables, We're and a for environment XX% driver revenue in the on down half, just revenue about business, customer And in as We the sequential and down was first the $XX million instrument places this $X decline the first XX%. and encouraged But we revenue contributed impact in orders mentioned, about uptick seeing XXXX of impact and quarter, by mentioned, in pharma biggest key quarter.
Service growth the million XX% down XX%. early million the $XX second down to uptick the from year, SomaScan-related this in sample accounts. the quarter, versus was over correlated but in first is continue by cycles half are instrument on extended constrained second Michael saw delivery QX our down of about we million as
to this in to of that half flat placement And first as and Support move the over the this over second decrease improve the time. back the consumables, expect continue grow 'XX, X% in in as XXXX. to revenue continue we roughly revenue source million expand base will half our of instrument highly expect contributed XXXX, correlated $X Services with $XX is year.
Instrument like the We through with we over and we million installed quarter,
to 'XX, genomics we're to SomaScan over where segment variability the Proteomics the growth revenue, positive and more OEM segment our segment flow driving to as expectations over assay as is our down imaging genomics It cytometry, XX% quarter manage XX% and half half prone customer term. the in be we our the margin its of strategic as plan Turning quickly through first down purchasing highest XX% support first whole mid-single over and our in but that's on represents years, long the X% second as and in business, from was Proteomics transition, and customer XXXX, quarter of long the and services continue the but we includes rightsized kits X services our -- was business to with growth instrument focusing segment the targeting revenue line well XX% business now accounts. contribution to digits, our in for term.
Genomics key for today instruments, expect We've OpEx profitable past segment. This of a revenue. our the segment consumables cycles the
Moving to our operating starting gross with performance, margin.
pro the XX% XX% Our to in non-GAAP assay basis capacity basis see was basis from XX% to year. -- versus or first same combined instruments quarter, headwinds points upgrade in impact and the gross of in half the forma XX% XXX around compared of from in a margin SomaScan services our related on XXXX, quarter the In second strategic field. lower XXX and for did replace to utilization last period second we decisions points volumes lower over the 'XX
non-GAAP Excluding continue would decline recover, encouragingly, to gross the XX%, continue our with some we impact have have expect of margin beginning in early the to This expansion. decrease. these been items, to headwinds is as an our revenue gross of But improvements corrective that run margin see and SomaScan volumes costs second replacement on actions half expected beginning XXXX. impact upgrade our to our longer-term cost warranty are to indicator see we're rate
grow transitory all costs into operations. in past gross and our with we headwinds, efficiency improvements to So still as said, over time, we especially confident across move margins that these combined drive we sales, non-GAAP remain the we our ability drive mid-XXs
expenses. operating to Moving
we're the that plan just forma our we're combined OpEx of report $XX on XX% the pleased that million about began on $XX 'XX. million, quarter, of pro reduction reduction of to a expense in continued expense by operating initiatives. Michael second decreased mentioned, under On or our half basis, ahead in As traction second reflecting non-GAAP
by as OpEx preserving cost non-GAAP for we half decreased to slight R&D where of approach million to core R&D as in by For or XXXX, the our strategic the the take $XX XX%, necessary. reduction and thoughtful, second first investments actions, spend a seen our continue quarter, about uptick
we've operationalized XXXX off million. to end half. the by and the before Today, before committed we in $XX reductions any reductions we accelerate now expense $XXX of million implemented cost from reductions versus our earlier full remaining initiatives the year. of jumping the million the $XX operationalize we future year impact restructuring these impact annualized We've operating plan second all of this the that And in to see target are point
that these in of reflected in to reach We're impact generate $XX total, we expect we expect actually adjusted more leveraging remain diversified the value with the year than full there. on savings to committed in P&L and the ever XXXX.
Based if will 'XX under costs manage scale breakeven our in full portfolio, now enthusiastic the million So show structure, about EBITDA of prepared P&L we more get aggressively we're for efforts, the cost to these up combined to where our over XXXX. even needed
cash In we it's over growth.
And while investments cash, as said, impact and million maintain Michael repurchases.
But about excluding the million, a flow even the expected I ago, reduction and as as to merger-related it and the pro and equivalents, sequentially ended in We second we revenue for of time, share nonoperating same transaction commercial about said, long-term short-term due the our burn $XXX items, operating we $XX burn merger-related R&D support cash several in to level. about focused about the payments cash of $XX our a quarter, was burn quarter reduced and X% typically expenses quarter in first to high balance investments adjusted uses the year was pipeline representing cash over at forma continue during these finally, the At sheet. still a combined quarter, other cash the made second restricted cash million a aggregate, improved in cash. and our
we about activities. we do So the first fund quarter, to and positioned saw needs and cash well thoughtful cash structure for capital one in and restructuring But cash.
And such remain outlays we're final to opportunities both the expect think future we additional strategic while nonoperating to including the very cash M&A, levels use on these continued update breakeven.
And not the arise, about second integration initiatives. disciplined when support at then combined merger, related of and as any business M&A flow we
Board new to program $XX we half XX.X of of about $XX our up approved As previously repurchase million repurchase share million common X% share. of the about price XXXX, in $X.XX at announced February, the million per we were purchased first average of in shares shares, a outstanding through cash an approximately
in As committed available still assets. on call, back towards in with We under suspended call our the responsible create our we turn first And the plan for for long-term buyback remain authorization, we the May shareholders. Xnd.
And Q&A. I'll we million quarter that, the room where we to summary, to $XX shared our operator have value
